Literature DB >> 25757923

Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.

Yosuke Hashimoto1, Taro Shimizu, Amr Selim Abu Lila, Tatsuhiro Ishida, Hiroshi Kiwada.   

Abstract

PEGylation, which is the surface modification of nanocarriers with polyethylene glycol (PEG), has increased the circulation time and reduced the immunogenic responses to nanocarriers. However, many reports have demonstrated that the intravenous injection of sterically stabilized PEGylated liposome (SL) causes an accelerated blood clearance (ABC) of subsequent doses via anti-PEG immunoglobulin M (IgM)-mediated complement activation. In the present study, the relationships between serum anti-PEG IgM concentration, the intensity of complement activation and the hepatic clearance of SL were quantitatively investigated for their role in the ABC phenomenon. Interestingly, with increasing serum anti-PEG IgM concentrations, the intensity of complement activation increased linearly, while the intensity of the hepatic clearance of SL was increased and then saturated. In addition, only 15-17% of anti-PEG IgM in blood circulation induced by SL at different doses was associated with a second dose SL. The present results indicate that it is the hepatic uptake of SL that is the limiting step in the ABC phenomenon, rather than the association of anti-PEG IgM to the SL and a subsequent complement activation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25757923     DOI: 10.1248/bpb.b14-00653

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  10 in total

1.  Multiple Administrations of Viral Nanoparticles Alter in Vivo Behavior-Insights from Intravital Microscopy.

Authors:  Sourabh Shukla; R Dixon Dorand; Jay T Myers; Sarah E Woods; Neetu M Gulati; Phoebe L Stewart; Ulrich Commandeur; Alex Y Huang; Nicole F Steinmetz
Journal:  ACS Biomater Sci Eng       Date:  2016-03-30

Review 2.  Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications.

Authors:  Raziye Mohammadpour; Marina A Dobrovolskaia; Darwin L Cheney; Khaled F Greish; Hamidreza Ghandehari
Journal:  Adv Drug Deliv Rev       Date:  2019-07-08       Impact factor: 15.470

3.  Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease.

Authors:  Hyung-Jun Im; Christopher G England; Liangzhu Feng; Stephen A Graves; Reinier Hernandez; Robert J Nickles; Zhuang Liu; Dong Soo Lee; Steve Y Cho; Weibo Cai
Journal:  ACS Appl Mater Interfaces       Date:  2016-07-07       Impact factor: 9.229

Review 4.  Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors:  Anna N Ilinskaya; Marina A Dobrovolskaia
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-07       Impact factor: 4.219

5.  Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.

Authors:  Christine E Henry; Ying-Ying Wang; Qi Yang; Thuy Hoang; Sumon Chattopadhyay; Timothy Hoen; Laura M Ensign; Kenetta L Nunn; Holly Schroeder; Justin McCallen; Thomas Moench; Richard Cone; Steve R Roffler; Samuel K Lai
Journal:  Acta Biomater       Date:  2016-07-14       Impact factor: 8.947

6.  Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon.

Authors:  Yuqing Su; Mengyang Liu; Yan Xiong; Junqiang Ding; Xinrong Liu; Yanzhi Song; Yihui Deng
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

7.  The accelerated blood clearance phenomenon of PEGylated nanoemulsion upon cross administration with nanoemulsions modified with polyglycerin.

Authors:  Yuqing Su; Lirong Wang; Kaifan Liang; Mengyang Liu; Xinrong Liu; Yanzhi Song; Yihui Deng
Journal:  Asian J Pharm Sci       Date:  2017-08-07       Impact factor: 6.598

Review 8.  Revisiting the outstanding questions in cancer nanomedicine with a future outlook.

Authors:  M S Sudheesh; K Pavithran; Sabitha M
Journal:  Nanoscale Adv       Date:  2021-12-22

Review 9.  Roadmap and strategy for overcoming infusion reactions to nanomedicines.

Authors:  Janos Szebeni; Dmitri Simberg; África González-Fernández; Yechezkel Barenholz; Marina A Dobrovolskaia
Journal:  Nat Nanotechnol       Date:  2018-10-22       Impact factor: 39.213

Review 10.  Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.

Authors:  Marina A Dobrovolskaia; Mark Bathe
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.